General Information of Drug (ID: DMEJT5Z)

Drug Name
SN-32793 Drug Info
Synonyms
PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMEJT5Z

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Epidermal growth factor receptor (EGFR) DTT EGFR 6.045 4.991 5.317 5.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 5.84E-05 0.32 0.55
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01631279) A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).